These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 17332943

  • 1. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Oncol; 2007 Apr; 30(4):1019-28. PubMed ID: 17332943
    [Abstract] [Full Text] [Related]

  • 2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G.
    Clin Cancer Res; 2005 Jan 01; 11(1):49-57. PubMed ID: 15671527
    [Abstract] [Full Text] [Related]

  • 4. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
    Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M.
    Cancer Lett; 2005 Aug 26; 226(2):123-31. PubMed ID: 16039952
    [Abstract] [Full Text] [Related]

  • 5. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, Groot K, Hohla F, Zarandi M, Varga JL.
    Prostate; 2008 Dec 01; 68(16):1763-72. PubMed ID: 18729085
    [Abstract] [Full Text] [Related]

  • 6. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K.
    Cancer Res; 1994 Nov 15; 54(22):5895-901. PubMed ID: 7954420
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K.
    Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027
    [Abstract] [Full Text] [Related]

  • 8. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ.
    Br J Cancer; 1994 Nov 01; 70(5):886-92. PubMed ID: 7947094
    [Abstract] [Full Text] [Related]

  • 9. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K, Schally AV, Rick FG, Block NL, Vidaurre I, Halmos G, Szalontay L.
    Anticancer Drugs; 2012 Oct 01; 23(9):906-13. PubMed ID: 22926257
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
    Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL.
    Proc Natl Acad Sci U S A; 2003 Dec 23; 100(26):15836-41. PubMed ID: 14660794
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
    Kiaris H, Schally AV, Sun B, Armatis P, Groot K.
    Oncogene; 1999 Nov 25; 18(50):7168-73. PubMed ID: 10597318
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J, Reile H, Halmos G, Groot K, Schally AV.
    Cancer Res; 1994 Jan 01; 54(1):169-74. PubMed ID: 7903203
    [Abstract] [Full Text] [Related]

  • 13. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
    Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL.
    Int J Cancer; 2004 Nov 20; 112(4):570-6. PubMed ID: 15382037
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival.
    Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E.
    J Pathol; 1999 Aug 20; 188(4):369-77. PubMed ID: 10440746
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.